CSL Behring Email Format

Biotechnology Research
25,001-50,000 employees
Melbourne, VIC, Australia

CSL Behring is a global biopharmaceutical company that develops and delivers lifesaving medicines for haemophilia, immune deficiencies, influenza prevention, and nephrology across more than 100 countries.

Find contacts at CSL Behring

Search our verified sources for decision-makers, emails, and titles.

Start searching
VERIFIED BY CLAY

first.last@cslbehring.com

Company Overview

Industry
Biotechnology Research
Founded
1916
Headquarters
Melbourne, VIC, Australia
Revenue
$10B-$25B
FUNDING Stage
Public
Key Executives
Gordon Naylor (CEO & Managing Director), Ken Lim (Chief Financial Officer), Mary Oates (Executive Vice President and Chief Operating Officer)

Tech Stack

Amazon Web Services

Cloud

Signup

to know

Signup

to know

Signup

to know

Key Executives

Chief Executive Officer

Find the current person →

Chief Finance Officer

Find the current person →

Chief Operating Officer

Find the current person →

Chief Technology Officer

Find the current person →

Chief Marketing Officer

Find the current person →

Chairman

Find the current person →

4.9/5 on G2
40K+ GTM professionals
SOC 2 Type II certified

Frequently Asked Questions

What is the email format of CSL Behring?

CSL Behring uses the first.last format on cslbehring.com, so Jane Smith would be jane.smith@cslbehring.com.

What therapeutic areas does CSL Behring focus on?

CSL Behring focuses on immunology, hematology, cardiovascular and metabolic diseases, respiratory conditions, and transplant medicine, developing plasma-derived and recombinant therapies for rare and serious diseases in more than 100 countries.

How can I find and verify a specific CSL Behring contact's email address?

Since CSL Behring follows the first.last@cslbehring.com format consistently, you can build an address from a contact's name and verify it using a tool like Clay, which can confirm deliverability before you reach out.

Who leads CSL Behring as its chief executive?

Gordon Naylor serves as CEO and Managing Director of CSL Behring. Mary Oates is the Executive Vice President and Chief Operating Officer, and Ken Lim holds the role of Chief Financial Officer.

What is HEMGENIX and how does it relate to CSL Behring's gene therapy pipeline?

HEMGENIX is CSL Behring's FDA-approved gene therapy for adults with hemophilia B, making it the first gene therapy of its kind approved by the FDA. It is a one-time infusion designed to provide sustained factor IX activity and reduce abnormal bleeding episodes.

Share Article

Get access to more people and company data using Clay

Leverage the power of 100+ data providers for industry-leading data coverage & quality.

4.9 rating

More Articles